Stockwatch: Bluebird, Arrowhead And Short Memories
Executive Summary
Last year's platform failure and back to the drawing board status of bluebird bio was all forgotten last week as data on a few patients treated with its CAR-T therapy were released. It seems that investors are quick to forget similar failed or problematic products at Arrowhead, uniQure and Juno.
You may also be interested in...
Stock Watch: The Stubborn Hurdle Of Chronic Hepatitis B
Most of the money raised by biotech companies to address chronic hepatitis B has resulted in failed programs. But wait, a glimmer of light from yonder pharma breaks.
Stockwatch: Is Alnylam’s Rare Disease Business Model Sustainable?
Alnylam’s fourth-quarter and full-year 2019 earnings announcement was only one of eight announcements made by the company since early February. With the fundamental basis of its orphan drug business model still unvalidated by a profit, perhaps the more recent announcements are meant to distract investors’ attention with different metrics.
RNA Therapeutics Near A Tipping Point, Says Silence’s CEO
With recent product approvals and the development of new chemistries and delivery technologies, the RNA-based drugs sector is undergoing rapid change, and UK-based Silence Therapeutics is aiming to be part of that evolution.